4502.T Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 09:15):

Stats
Объем за сегодня	3.19M
Средний объем	4.46M
Рыночная капитализация	6 415.37B
EPS	¥0 ( 2024-02-01 )
Дата следующего отчета о доходах	( ¥1.100 ) 2024-05-08
Last Dividend	¥90.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	36.36
ATR14	¥1.540 (0.04%)

Объем Корреляция

Длинно: 0.14 (neutral)

Кратко: 0.63 (weak)

Signal:(52.758) Neutral

Takeda Pharmaceutical Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Takeda Pharmaceutical Корреляция - Валюта/Сырье

0.17
( neutral )

0.08
( neutral )

0.03
( neutral )

-0.25
( neutral )

-0.20
( neutral )

-0.36
( neutral )

Takeda Pharmaceutical Финансовые показатели

Annual	2022
Выручка:	¥4 027.48B
Валовая прибыль:	¥2 783.41B (69.11 %)
EPS:	¥204.29

FY	2022
Выручка:	¥4 027.48B
Валовая прибыль:	¥2 783.41B (69.11 %)
EPS:	¥204.29

FY	2022
Выручка:	¥3 569.01B
Валовая прибыль:	¥2 462.16B (68.99 %)
EPS:	¥147.14

FY	2021
Выручка:	¥3 197.81B
Валовая прибыль:	¥2 203.50B (68.91 %)
EPS:	¥240.72

Financial Reports:

No articles found.

Takeda Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥90.00 (N/A)	¥0 (N/A)	¥90.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Takeda Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.76 - low (58.20%) | Divividend Growth Potential Score: 4.33 - Stable (13.47%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥16.50	2000-03-28
Last Dividend	¥90.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	48	--
Total Paid Out	¥3 458.50	--
Avg. Dividend % Per Year	0.00%	--
Score	2.84	--
Div. Sustainability Score	4.76
Div.Growth Potential Score	4.33
Div. Directional Score	4.54	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

2.84

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6638.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
5965.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
4662.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
3902.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
3134.T	Ex Dividend Junior	2024-04-26	Annually	0.00%
2004.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9613.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8550.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
7872.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
7013.T	No Dividend Player	2023-09-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0427	1.500	9.15	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0125	1.200	9.58	10.00	[0 - 0.3]
returnOnEquityTTM	0.0263	1.500	-0.819	-1.228	[0.1 - 1]
payoutRatioTTM	1.619	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.064	0.800	9.68	7.74	[1 - 3]
quickRatioTTM	0.465	0.800	-1.972	-1.578	[0.8 - 2.5]
cashRatioTTM	0.126	1.500	-0.409	-0.614	[0.2 - 2]
debtRatioTTM	0.328	-1.500	4.53	-6.80	[0 - 0.6]
interestCoverageTTM	1.450	1.000	-0.574	-0.574	[3 - 30]
operatingCashFlowPerShareTTM	466.22	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	-82.25	2.00	-10.00	-10.00	[0 - 20]
debtEquityRatioTTM	0.692	-1.500	7.23	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.675	1.000	2.08	2.08	[0.2 - 0.8]
operatingProfitMarginTTM	0.0750	1.000	-0.500	-0.500	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.157	1.000	-0.240	-0.240	[0.2 - 2]
assetTurnoverTTM	0.293	0.800	-1.379	-1.103	[0.5 - 2]
Total Score				4.76

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	36.00	1.000	6.47	0	[1 - 100]
returnOnEquityTTM	0.0263	2.50	-0.526	-1.228	[0.1 - 1.5]
freeCashFlowPerShareTTM	-82.25	2.00	-10.00	-10.00	[0 - 30]
dividendYielPercentageTTM	4.60	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	466.22	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	1.619	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.927	1.500	7.15	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.175	1.000	8.11	0	[0.1 - 0.5]
Total Score				4.33

Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.